caa a22 4500 605478651 CHVBK 20210128100406.0 cr unu---uuuuu 210128e20150101xx s 000 0 eng 10.1007/s10741-014-9435-x doi (NATIONALLICENCE)springer-10.1007/s10741-014-9435-x Bone marrow-derived mesenchymal stem cells for the treatment of heart failure [Elektronische Daten] [Takuya Narita, Ken Suzuki] Heart failure remains a major cause of death and disability, requiring rapid development of new therapies. Bone marrow-derived mesenchymal stem cell (MSC)-based therapy is an emerging approach for the treatment of both acute and chronic heart failure. Following successful experimental studies in a range of models, more than 40 clinical trials of MSC-based therapy for heart failure have now been registered, and the results of completed clinical trials so far have shown feasibility and safety of this approach with therapeutic potential suggested (though preliminarily). However, there appear to be several critical issues to be solved before this treatment could become a widespread standard therapy for heart failure. In this review, we comprehensively and systemically summarize a total of 73 preclinical studies and 11 clinical trial reports published to date. By analyzing the data in these reports, (1) improvement in the cell delivery method to the heart in order to enhance donor cell engraftment, (2) elucidation of mechanisms underpinning the therapeutic effects of the treatment differentiation and/or treatment secretion, and (3) validation of the utility of allogeneic MSCs which could enhance the efficacy and expand the application/indication of this therapeutic approach are highlighted as future perspectives. These important respects are further discussed in this review article with referencing latest scientific and clinical information. Springer Science+Business Media New York, 2014 Mesenchymal stem cell nationallicence Cell transplantation nationallicence Heart failure nationallicence Experimental nationallicence Clinical trial nationallicence Narita Takuya Cardiothoracic Surgery, National Heart Centre, Singapore, Singapore aut Suzuki Ken William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, EC1M 6BQ, London, UK aut Heart Failure Reviews Springer US; http://www.springer-ny.com 20/1(2015-01-01), 53-68 1382-4147 20:1<53 2015 20 10741 https://doi.org/10.1007/s10741-014-9435-x text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10741-014-9435-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Narita Takuya Cardiothoracic Surgery, National Heart Centre, Singapore, Singapore aut NATIONALLICENCE 700 1- Suzuki Ken William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, EC1M 6BQ, London, UK aut NATIONALLICENCE 773 0- Heart Failure Reviews Springer US; http://www.springer-ny.com 20/1(2015-01-01), 53-68 1382-4147 20:1<53 2015 20 10741